Colleen Cutcliffe: The Biochemist Who Bottled the Unbottleable
The bacterium that made her company famous dies on contact with air. Colleen Cutcliffe bet that a team of actual biologists could culture it anyway — and the bet began in a NICU, over a four-pound baby on her fourth week of antibiotics.
Colleen Cutcliffe is the co-founder and CEO of Pendulum Therapeutics, the first company to commercialize the oxygen-averse gut bacterium Akkermansia muciniphila. Her credentials are checkable: a Wellesley biochemistry degree, a PhD in biochemistry and molecular biology from Johns Hopkins confirmed on the university's own site, a cancer-biology postdoc, Parkinson's drug-discovery work at Elan Pharmaceuticals, and a senior biology role at Pacific Biosciences, where she met her two co-founders. She is a research scientist, not a physician. The founding story is personal and documented: her first daughter was born about eight weeks premature at just over four pounds, spent four weeks in the NICU on multiple precautionary antibiotic courses, and later showed metabolic differences and food sensitivities that set Cutcliffe on the question of what the antibiotics took and whether it could be put back. The company that resulted raised Sequoia money, put one formulation through a randomized human trial in type 2 diabetes, added Halle Berry as Chief Communications Officer in 2023, and launched its GLP-1 Probiotic flagship in March 2024. As founder and CEO she holds a full financial stake in the products; our separate Gut Check audit sizes the evidence independently. Educational, not medical advice.
The bacterium that made Colleen Cutcliffe’s company famous dies on contact with air. Akkermansia muciniphila lives in the mucus lining of your gut, wants nothing to do with oxygen, and for years was the microbe everyone in the field cited and nobody could bottle. Cutcliffe’s bet — that a team of actual biologists could culture it at scale while the rest of the supplement industry kept freeze-drying the easy stuff — is the entire story of Pendulum, the Sequoia-backed company she runs, and the reason a probiotic brand gets discussed in the same sentences as drug companies. Whatever you make of the shelf price, the microbiology was real, it was hard, and she did it first.
The credentialsA PhD who did the unglamorous years
Cutcliffe is a biochemist by training, not a physician — and her scientific pedigree runs deep and checkable. A biochemistry degree from Wellesley, then a PhD in biochemistry and molecular biology at Johns Hopkins, where her thesis dissected ubiquitin signaling — the cell’s protein-disposal system — under the late Cecile Pickart, one of the field’s giants. Then the working-scientist decade almost no wellness founder has: a postdoc in cancer biology at Children’s Memorial Hospital in Chicago, drug-discovery work in Elan Pharmaceuticals’ Parkinson’s group, and a run as Senior Manager of Biology at Pacific Biosciences, the DNA-sequencing company — where she met the two scientists who would become her co-founders.
The originFour pounds, four weeks, and a decade of consequences
The company’s founding story is not a marketing invention; Pendulum tells it in clinical detail. Cutcliffe’s first daughter, Annabella, arrived roughly eight weeks early, weighing just over four pounds, and spent four weeks in the NICU — where, as a precaution for so fragile a patient, she received multiple courses of antibiotics. The antibiotics did their job. They also, in Cutcliffe’s reading, leveled the microbiome an infant is supposed to spend those weeks assembling — and as Annabella grew, her mother the biologist watched differences accumulate: metabolism, food sensitivities, patterns the rest of the family didn’t share. The scientific question underneath — what exactly did the antibiotics take, and can it be put back? — took nearly a decade of R&D to become a product, and it is not a coincidence that the product answers her daughter’s question at industrial scale.
The founding question was a mother’s: what did the antibiotics take, and can it be put back? The company is the question, scaled.
The workWhat Pendulum actually became
Pendulum Therapeutics — she co-founded it in the mid-2010s and has run it since — became the first company to commercialize Akkermansia, and the rare supplement maker to put its flagship through a randomized, placebo-controlled human trial, in type 2 diabetes patients. It also became a commercial machine: Forbes coverage, a national grocery rollout, the biggest wellness podcasts, and Halle Berry joining as Chief Communications Officer and equity owner in 2023. Cutcliffe herself has become one of the microbiome’s most effective explainers — fluent, funny, and notably more careful with claims in long interviews than her industry’s ads tend to be. How far the company’s evidence actually stretches — one human trial, on one product, with the GLP-1 flagship resting on preclinical work — is a question we answered separately and independently in our Gut Check audit of Pendulum; this profile and that audit are deliberately two different documents.
The disclosure mapWhere her interests sit
The commercial map here is short because it is total: Cutcliffe is co-founder and chief executive of the company whose products this site has audited, with the financial stake that implies; she chairs no clinic and treats no patients, and nothing she says in interviews constitutes medical guidance. That is not a criticism — it is the correct frame for reading any founder, and she has never pretended otherwise. Her scientific credibility is the real thing; her incentives are the obvious thing; a careful reader holds both. This profile is educational, is not medical advice, and was prepared with no input from Pendulum.